Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc's clinical advancements in treating untreatable eye diseases position the company favorably in the biopharmaceutical sector, particularly with their Phase 3 DRAGON trial demonstrating a statistically significant 36% reduction in atrophic lesion growth in patients with Stargardt disease. The company’s focus on younger patients and the promising results from the PHOENIX trial suggest potential for indication expansion, with emixustat showing a notable 40.8% reduction in lesion progression compared to placebo. Furthermore, the broadened safety database for tinlarebant, especially in older patients, enhances prospects for regulatory approval and market acceptance, reinforcing Belite Bio's strategic positioning in a niche sector with unmet medical needs.

Bears say

The analysis indicates a negative outlook on Belite Bio Inc.'s stock primarily due to uncertainties surrounding the therapeutic candidates' clinical trials and commercial viability. The company's projected revenue of $3.1 billion post-patent expiration for tinlarebant appears unsupported, considering the substantial R&D expenditure estimated at $2.7 billion and challenges in achieving market penetration in larger indications. Additionally, multiple risks, including potential clinical trial failures, regulatory hurdles, and dilution threats, further exacerbate concerns regarding the company's ability to deliver financially in the future.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $198, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $198, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.